Literature DB >> 26537831

Treatment for pulmonary hypertension due to left heart diseases.

Kazufumi Nakamura1.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26537831     DOI： 10.1038/hr.2015.116

Source DB:  PubMed          Journal:  Hypertens Res        ISSN： 0916-9636            Impact factor:   3.872


× No keyword cloud information.
  10 in total

1.  Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study.

Authors:  Marco Guazzi; Marco Vicenzi; Ross Arena; Maurizio D Guazzi
Journal:  Circulation       Date:  2011-06-27       Impact factor: 29.690

2.  Combination therapy adding tadalafil to existing ambrisentan in patients with pulmonary arterial hypertension.

Authors:  Akihiro Hirashiki; Takahisa Kondo; Toyoaki Murohara
Journal:  Hypertens Res       Date:  2014-03-20       Impact factor: 3.872

3.  Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy.

Authors:  Eiki Takimoto; Hunter C Champion; Manxiang Li; Diego Belardi; Shuxun Ren; E Rene Rodriguez; Djahida Bedja; Kathleen L Gabrielson; Yibin Wang; David A Kass
Journal:  Nat Med       Date:  2005-01-23       Impact factor: 53.440

4.  Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study.

Authors:  Milton Packer; John McMurray; Barry M Massie; Abraham Caspi; Vincent Charlon; Alain Cohen-Solal; Wolfgang Kiowski; William Kostuk; Henry Krum; Barry Levine; Paolo Rizzon; Jordi Soler; Karl Swedberg; Susan Anderson; David L Demets
Journal:  J Card Fail       Date:  2005-02       Impact factor: 5.712

5.  Comparative effectiveness of sildenafil for pulmonary hypertension due to left heart disease with HFrEF.

Authors:  Rong Jiang; Lan Wang; Chang-Tai Zhu; Ping Yuan; Bigyan Pudasaini; Qin-Hua Zhao; Su-Gang Gong; Jing He; Jin-Ming Liu; Qing-Hua Hu
Journal:  Hypertens Res       Date:  2015-07-23       Impact factor: 3.872

6.  A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST).

Authors:  R M Califf; K F Adams; W J McKenna; M Gheorghiade; B F Uretsky; S E McNulty; H Darius; K Schulman; F Zannad; E Handberg-Thurmond; F E Harrell; W Wheeler; J Soler-Soler; K Swedberg
Journal:  Am Heart J       Date:  1997-07       Impact factor: 4.749

7.  Additional use of a phosphodiesterase 5 inhibitor in patients with pulmonary hypertension secondary to chronic systolic heart failure: a meta-analysis.

Authors:  Xiaojing Wu; Te Yang; Qi Zhou; Shuangfei Li; Lan Huang
Journal:  Eur J Heart Fail       Date:  2013-12-31       Impact factor: 15.534

8.  Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure?

Authors:  Paul R Kalra; James C C Moon; Andrew J S Coats
Journal:  Int J Cardiol       Date:  2002-10       Impact factor: 4.164

9.  Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.

Authors:  Margaret M Redfield; Horng H Chen; Barry A Borlaug; Marc J Semigran; Kerry L Lee; Gregory Lewis; Martin M LeWinter; Jean L Rouleau; David A Bull; Douglas L Mann; Anita Deswal; Lynne W Stevenson; Michael M Givertz; Elizabeth O Ofili; Christopher M O'Connor; G Michael Felker; Steven R Goldsmith; Bradley A Bart; Steven E McNulty; Jenny C Ibarra; Grace Lin; Jae K Oh; Manesh R Patel; Raymond J Kim; Russell P Tracy; Eric J Velazquez; Kevin J Anstrom; Adrian F Hernandez; Alice M Mascette; Eugene Braunwald
Journal:  JAMA       Date:  2013-03-27       Impact factor: 56.272

Review 10.  Epoprostenol sodium for treatment of pulmonary arterial hypertension.

Authors:  Yukihiro Saito; Kazufumi Nakamura; Satoshi Akagi; Toshihiro Sarashina; Kentaro Ejiri; Aya Miura; Aiko Ogawa; Hiromi Matsubara; Hiroshi Ito
Journal:  Vasc Health Risk Manag       Date:  2015-05-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.